Dicerna Stock Soars Following IPO Despite Potential Competition with Core Technology | GenomeWeb

Despite a lack of exclusivity for its core RNAi technology, Dicerna Pharmaceuticals continues to fly high following its Jan. 30 initial public offering, with its shares trading this week around $36 — more than twice their $15 debut price.

To one industry watcher, the success of Dicerna's IPO reflects a confluence of a strong biotech market and a resurgence in interest in RNAi as a therapeutic modality.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.